Table of Contents

1 Product Introduction and Overview

• 1.1 Product Definition
• 1.2 Product Specification
• 1.3 Global Market Overview
  • 1.3.1 Global Personalized Cancer Medicine Market Status and Forecast (2016-2027)
  • 1.3.2 Global Personalized Cancer Medicine Sales Value CAGR by Region
• 1.4 Market Drivers, Inhibitors
  • 1.4.1 Market Drivers
  • 1.4.2 Market Inhibitors
  • 1.4.3 COVID-19 Impact Analysis

2 Global Personalized Cancer Medicine Supply by Company

• 2.1 Global Personalized Cancer Medicine Sales Value by Company
• 2.2 Personalized Cancer Medicine Sales Area of Main Manufacturers
• 2.3 Trend of Concentration Rate

3 Global and Regional Personalized Cancer Medicine Market Status by Category

• 3.1 Personalized Cancer Medicine Category Introduction
  • 3.1.1 Monoclonal Antibodies
  • 3.1.2 Personalized Cancer Vaccines
  • 3.1.3 Other
• 3.2 Global Personalized Cancer Medicine Market by Category
• 3.3 North America: by Category
• 3.4 Europe: by Category
• 3.5 Asia Pacific: by Category
• 3.6 Central & South America: by Category
• 3.7 Middle East & Africa: by Category

4 Global and Regional Personalized Cancer Medicine Market Status by End User/Segment

• 4.1 Personalized Cancer Medicine Segment by End User/Segment
  • 4.1.1 Breast Cancer
  • 4.1.2 Lung Cancer
  • 4.1.3 Chronic Myeloid Leukaemia
  • 4.1.4 Bowel Cancer
  • 4.1.5 Other Cancer
• 4.2 Global Personalized Cancer Medicine Market by End User/Segment
• 4.3 North America: by End User/Segment
• 4.4 Europe: by End User/Segment
• 4.5 Asia Pacific: by End User/Segment
• 4.6 Central & South America: by End User/Segment
• 4.7 Middle East & Africa: by End User/Segment

5 Global Personalized Cancer Medicine Market Status by Region

• 5.1 Global Personalized Cancer Medicine Market by Region
• 5.2 North America Personalized Cancer Medicine Market Status
• 5.3 Europe Personalized Cancer Medicine Market Status
• 5.4 Asia Pacific Personalized Cancer Medicine Market Status
• 5.5 Central & South America Personalized Cancer Medicine Market Status
• 5.6 Middle East & Africa Personalized Cancer Medicine Market Status

6 North America Personalized Cancer Medicine Market Status

• 6.1 North America Personalized Cancer Medicine Market by Country
• 6.2 United States
• 6.3 Canada
• 6.4 Mexico

7 Europe Personalized Cancer Medicine Market Status

• 7.1 Europe Personalized Cancer Medicine Market by Country
• 7.2 Germany
• 7.3 France
• 7.4 UK
• 7.5 Italy
• 7.6 Russia
• 7.7 Spain

8 Asia Pacific Personalized Cancer Medicine Market Status

• 8.1 Asia Pacific Personalized Cancer Medicine Market by Country
• 8.2 China
• 8.3 Japan
• 8.4 Korea
• 8.5 Southeast Asia
• 8.6 India
• 8.7 Australasia

9 Central & South America Personalized Cancer Medicine Market Status

• 9.1 Central & South America Personalized Cancer Medicine Market by Country
• 9.2 Brazil
• 9.3 Argentina
• 9.4 Colombia

10 Middle East & Africa Personalized Cancer Medicine Market Status

• 10.1 Middle East & Africa Personalized Cancer Medicine Market by Country
• 10.2 Iran
• 10.3 Israel
• 10.4 Turkey
• 10.5 South Africa
• 10.8 Saudi Arabia

11 Major Downstream Customers Analysis

• 11.1 Customer One Analysis
• 11.2 Customer Two Analysis
• 11.3 Customer Three Analysis
• 11.4 Customer Four Analysis

12 Global Personalized Cancer Medicine Market Forecast by Category and by End User/Segment

• 12.1 Global Personalized Cancer Medicine Sales Value Forecast (2022-2027)
• 12.2 Global Personalized Cancer Medicine Forecast by Category
• 12.3 Global Personalized Cancer Medicine Forecast by End User/Segment

13 Global Personalized Cancer Medicine Market Forecast by Region/Country

• 13.1 Global Personalized Cancer Medicine Market Forecast by Region (2022-2027)
• 13.2 North America Market Forecast
• 13.3 Europe Market Forecast
• 13.4 Asia Pacific Market Forecast
• 13.5 Central & South America Market Forecast
• 13.6 Middle East & Africa Market Forecast

14 Key Participants Company Information

• 14.1 Takeda
  • 14.1.1 Company Information
  • 14.1.2 Personalized Cancer Medicine Product Introduction
  • 14.1.3 Takeda Personalized Cancer Medicine Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.1.4 SWOT Analysis
• 14.2 Roche
  • 14.2.1 Company Information
  • 14.2.2 Personalized Cancer Medicine Product Introduction
  • 14.2.3 Roche Personalized Cancer Medicine Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.2.4 SWOT Analysis
• 14.3 Novartis
  • 14.3.1 Company Information
  • 14.3.2 Personalized Cancer Medicine Product Introduction
  • 14.3.3 Novartis Personalized Cancer Medicine Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.3.4 SWOT Analysis
• 14.4 Merck
  • 14.4.1 Company Information
  • 14.4.2 Personalized Cancer Medicine Product Introduction
  • 14.4.3 Merck Personalized Cancer Medicine Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.4.4 SWOT Analysis
• 14.5 Johnson & Johnson
  • 14.5.1 Company Information
  • 14.5.2 Personalized Cancer Medicine Product Introduction
  • 14.5.3 Johnson & Johnson Personalized Cancer Medicine Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.5.4 SWOT Analysis
• 14.6 Celgene
  • 14.6.1 Company Information
  • 14.6.2 Personalized Cancer Medicine Product Introduction
  • 14.6.3 Celgene Personalized Cancer Medicine Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.6.4 SWOT Analysis
• 14.7 Bayer
  • 14.7.1 Company Information
  • 14.7.2 Personalized Cancer Medicine Product Introduction
  • 14.7.3 Bayer Personalized Cancer Medicine Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.7.4 SWOT Analysis
• 14.8 Astrazeneca
  • 14.8.1 Company Information
  • 14.8.2 Personalized Cancer Medicine Product Introduction
  • 14.8.3 Astrazeneca Personalized Cancer Medicine Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.8.4 SWOT Analysis
• 14.9 Astellas
  • 14.9.1 Company Information
  • 14.9.2 Personalized Cancer Medicine Product Introduction
  • 14.9.3 Astellas Personalized Cancer Medicine Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.9.4 SWOT Analysis
• 14.10 Amgen
  • 14.10.1 Company Information
  • 14.10.2 Personalized Cancer Medicine Product Introduction
  • 14.10.3 Amgen Personalized Cancer Medicine Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.10.4 SWOT Analysis
• 14.11 Agilent
• 14.12 Abbott

15 Conclusion

16 Methodology

Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Personalized Cancer Medicine market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Personalized Cancer Medicine market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

Segmented by Category
Monoclonal Antibodies
Personalized Cancer Vaccines
Other

Segmented by End User/Segment
Breast Cancer
Lung Cancer
Chronic Myeloid Leukaemia
Bowel Cancer
Other Cancer

Segmented by Country
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Spain
Asia Pacific
China
Japan
Korea
Southeast Asia
India
Australasia
Central & South America
Brazil
Argentina
Colombia
Middle East & Africa
Iran
Israel
Turkey
South Africa
Saudi Arabia

Key manufacturers included in this survey
Takeda
Roche
Novartis
Merck
Johnson & Johnson
Celgene
Bayer
Astrazeneca
Astellas
Amgen
Agilent
Abbott